Ferric carboxymaltose for anemia in late pregnancy: a randomized controlled trial.

Name: Αlpha¹ Rigor Record — Ferric carboxymaltose for anemia in late pregnancy: a randomized controlled trial.
Item: Ferric carboxymaltose for anemia in late pregnancy: a randomized controlled trial.
Rating: 59
Author: Αlpha¹

Pasricha SR, Moya E, Ataíde R, Mzembe G, Harding R, Mwangi MN, Zinenani T, Prang KH, Kaunda J, Mtambo OPL, Vokhiwa M, Mhango G, Mamani-Mategula E, Fielding K, Demir A, Von Dinklage N, Verhoef H, McLean AR, Manda-Taylor L, Braat S, Phiri KS

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.5★ (Weak), 0 critical, 2 high issues for “Ferric carboxymaltose for anemia in late pregnancy: a randomized controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
StatisticsStatistic did not reproduce−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Declared data/code links were not checked for liveness or content.

Problems surfaced4 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported randomized controlled trial. The design is rigorous with appropriate randomization, blinding of outcome assessors, power analysis, and pre-specified analyses. The main weaknesses are minor reporting inconsistencies (abstract vs. table percentages, a CI typo) and a few areas where additional detail could enhance reproducibility.

Both reviewers classified the study as interventional (RCT), and I adopt that classification. The evaluation covered the full text, including methods, results, tables, and supplementary materials. Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification component recomputed only a subset of tests (6 tests, 5 consistent, 1 inconsistent); the inconsistent test was not specified but aligns with the flagged CI typo. The citation check found no retracted or non-existent references.

5 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 5 tests: 5 consistent, 0 inconsistent; 3 recomputed directly from the reported test statistics, 2 via agent-written checks. 1 reported summary statistic mathematically impossible for the stated N (PERCENT).

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites global and regional anemia prevalence, WHO recommendations, and the limitations of oral iron in late pregnancy. It references the prior REVAMP trial and explains how the current trial addresses the gap by targeting the third trimester. The rationale for FCM is well-argued based on its rapid effect and prior findings.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work, a logical rationale, and addresses limitations of prior research.

Evidence

paraphrase[Introduction, paragraph 1-3]

“We previously evaluated the efficacy and safety of a single dose of FCM (compared to standard-of-care (SOC) oral iron) to treat moderate or severe anemia in the second trimester of pregnancy in Malawian women (REVAMP).”

direct quote[Introduction, paragraph 3]

“We therefore reasoned that in the third trimester, when childbirth is impending, FCM may offer an ideal solution to rapidly optimize hemoglobin concentration and alleviate the risk of anemia.”